Sorry Joe Wolf I should have explained myself better
1. With URB you are quite right that there was a base management fee plus commissions. This is the “double layering” of fees that I was referring to that was certainly an issue. I remember discovering that for the first time on this forum and kicking myself for not picking it up in my reading. So I’m not trying to claim it was a roaring success just provide my different opinion for discussion as I think it’s relevant to the future of SOL
2. The discount I referred to is the gap between the inferred net asset value of BKW and its current share price. I made up a bit of a model breaking this down and posted it in the forum for that stock if you want to take a look but a little over $20 of that asset value is in the SOL shareholding so it could reduce pretty quickly if SOL is indeed a bit overvalued as you point out (I tend to agree on that one and think fair value is between $29 and $30)
- Forums
- ASX - By Stock
- SOL
- Ann: WHSP 2023 AGM Presentation
SOL
washington h soul pattinson & company limited
Add to My Watchlist
0.00%
!
$41.53

Ann: WHSP 2023 AGM Presentation, page-16
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$41.53 |
Change
0.000(0.00%) |
Mkt cap ! $15.27B |
Open | High | Low | Value | Volume |
$41.40 | $41.93 | $41.40 | $18.47M | 444.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 518 | $41.52 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$41.66 | 2097 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 518 | 41.520 |
1 | 2195 | 41.450 |
2 | 2678 | 41.420 |
2 | 931 | 41.400 |
1 | 725 | 41.380 |
Price($) | Vol. | No. |
---|---|---|
41.660 | 2097 | 1 |
41.690 | 951 | 1 |
41.710 | 687 | 1 |
41.780 | 1722 | 1 |
41.820 | 551 | 2 |
Last trade - 16.11pm 25/06/2025 (20 minute delay) ? |
Featured News
SOL (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
SPONSORED BY The Market Online